There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Steris (STE – Research Report), Benitec Biopharma (BNTC – Research Report) and Bicycle Therapeutics (BCYC – Research Report) with bullish sentiments.
Steris (STE)
In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Steris, with a price target of $240.00. The company’s shares closed last Tuesday at $194.84.
According to TipRanks.com, Turkaly is a 3-star analyst with an average return of
Steris has an analyst consensus of Strong Buy, with a price target consensus of $223.75, implying a 14.3% upside from current levels. In a report issued on February 9, Stephens also maintained a Buy rating on the stock with a $220.00 price target.
See today’s best-performing stocks on TipRanks >>
Benitec Biopharma (BNTC)
JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Benitec Biopharma today and set a price target of $4.00. The company’s shares closed last Tuesday at $0.24, close to its 52-week low of $0.13.
According to TipRanks.com, Tuerkcan is a 1-star analyst with an average return of
Benitec Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
Bicycle Therapeutics (BCYC)
JMP Securities analyst Reni Benjamin reiterated a Buy rating on Bicycle Therapeutics today and set a price target of $46.00. The company’s shares closed last Tuesday at $24.91.
According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Bicycle Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $51.17, representing a 99.1% upside. In a report issued on February 10, Barclays also assigned a Buy rating to the stock with a price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on STE:
